Celyad Oncology SA (CLYYF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.97 Million EUR | -35.2% |
| 2022 | 15.39 Million EUR | -57.58% |
| 2021 | 36.3 Million EUR | 3.46% |
| 2020 | 35.09 Million EUR | -20.64% |
| 2019 | 44.21 Million EUR | 14.23% |
| 2018 | 38.71 Million EUR | 28.64% |
| 2017 | 30.09 Million EUR | -37.21% |
| 2016 | 47.92 Million EUR | -0.27% |
| 2015 | 48.05 Million EUR | 177.89% |
| 2014 | 17.29 Million EUR | 11.65% |
| 2013 | 15.48 Million EUR | 2.85% |
| 2012 | 15.05 Million EUR | 149.42% |
| 2011 | 6.03 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.58 Million EUR | 0.0% |
| 2023 Q4 | 9.97 Million EUR | 0.0% |
| 2023 Q2 | 11.15 Million EUR | 0.0% |
| 2022 Q3 | - USD | N/A |
| 2022 FY | 15.39 Million EUR | -57.58% |
| 2022 Q1 | 32.72 Million EUR | -9.86% |
| 2022 Q2 | 32.49 Million EUR | -0.72% |
| 2022 Q4 | 32.03 Million EUR | 0.0% |
| 2021 Q1 | 36.78 Million EUR | 4.82% |
| 2021 FY | 36.3 Million EUR | 3.46% |
| 2021 Q4 | 36.3 Million EUR | -7.28% |
| 2021 Q3 | 39.15 Million EUR | 3.51% |
| 2021 Q2 | 37.82 Million EUR | 2.84% |
| 2020 FY | 35.09 Million EUR | -20.64% |
| 2020 Q4 | 35.09 Million EUR | 0.0% |
| 2020 Q2 | 45.44 Million EUR | 0.0% |
| 2019 Q4 | 44.21 Million EUR | 0.0% |
| 2019 FY | 44.21 Million EUR | 14.23% |
| 2019 Q2 | 40.43 Million EUR | 0.0% |
| 2018 Q2 | 36.37 Million EUR | 0.0% |
| 2018 Q4 | 38.71 Million EUR | 0.0% |
| 2018 FY | 38.71 Million EUR | 28.64% |
| 2017 Q4 | 30.09 Million EUR | 0.0% |
| 2017 Q2 | 43.04 Million EUR | 0.0% |
| 2017 FY | 30.09 Million EUR | -37.21% |
| 2016 Q4 | 47.92 Million EUR | 0.0% |
| 2016 FY | 47.92 Million EUR | -0.27% |
| 2016 Q2 | 43.36 Million EUR | 0.0% |
| 2015 Q4 | 48.05 Million EUR | 0.0% |
| 2015 FY | 48.05 Million EUR | 177.89% |
| 2015 Q2 | 58.4 Million EUR | 0.0% |
| 2014 Q4 | 17.29 Million EUR | 0.0% |
| 2014 FY | 17.29 Million EUR | 11.65% |
| 2014 Q2 | 16.12 Million EUR | 0.0% |
| 2013 FY | 15.48 Million EUR | 2.85% |
| 2013 Q4 | 15.48 Million EUR | 0.0% |
| 2013 Q2 | 16.16 Million EUR | 0.0% |
| 2012 FY | 15.05 Million EUR | 149.42% |
| 2012 Q4 | 15.05 Million EUR | 0.0% |
| 2011 FY | 6.03 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 81.281% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -4.133% |
| SQZ Biotechnologies Company | 50.03 Million USD | 80.06% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 86.232% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 83.092% |
| Mesoblast Limited | 188.44 Million USD | 94.705% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -159.073% |
| Genus plc | 485 Million USD | 97.943% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -70.78% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -296.53% |
| Marizyme, Inc. | 26.67 Million USD | 62.595% |
| ContraFect Corporation | 32.53 Million USD | 69.328% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -162.579% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -403.607% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -160.682% |
| Intellipharmaceutics International Inc. | 12 Million USD | 16.911% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 15.284% |
| MultiCell Technologies, Inc. | 1617.67 USD | -616713.071% |
| Accustem Sciences Inc. | 1.07 Million USD | -824.54% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 87.111% |
| EV Biologics, Inc. | 2.11 Million USD | -371.758% |
| Q BioMed Inc. | 8.13 Million USD | -22.686% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 87.969% |
| Neon Bloom, Inc. | 1.22 Million USD | -713.725% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -93.897% |
| Biomind Labs Inc. | 1.49 Million USD | -565.816% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 95.912% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 45.782% |
| Skye Bioscience, Inc. | 14.07 Million USD | 29.094% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -396.386% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -6922.063% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -5.41% |
| IMV Inc. | 37.93 Million USD | 73.696% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -4861.316% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -73.657% |
| GB Sciences, Inc. | 5.41 Million USD | -84.179% |
| Alpha Cognition Inc. | 7.16 Million USD | -39.265% |
| HST Global, Inc. | 593.59 Thousand USD | -1580.95% |
| CSL Limited | 18.62 Billion USD | 99.946% |
| Halberd Corporation | 728.71 Thousand USD | -1269.252% |
| Enzolytics Inc. | 365.26 Million USD | 97.268% |
| Resverlogix Corp. | 67.39 Million USD | 85.195% |
| Affymax, Inc. | 8.87 Million USD | -12.479% |
| SYBLEU INC | 681.41 Thousand USD | -1364.31% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1089.653% |
| argenx SE | 444.95 Million USD | 97.758% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 86.682% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -482.147% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 16.173% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -172.239% |
| AVAX Technologies, Inc. | 3.99 Million USD | -149.841% |
| Zenith Capital Corp. | 27.56 Thousand USD | -36092.825% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.247% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4080.948% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -167.198% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1365.555% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 91.596% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -10.349% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -14808.336% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -595.883% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 80.149% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -267.969% |
| BioStem Technologies, Inc. | 15.9 Million USD | 37.264% |
| ONE Bio Corp. | 27.49 Million USD | 63.711% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2047.196% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -36272.252% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -692.412% |
| Agentix Corp. | 2.51 Million USD | -297.442% |
| LadRx Corporation | 2.2 Million USD | -353.437% |
| Cell Source, Inc. | 15.8 Million USD | 36.875% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -22224.145% |
| Regen BioPharma, Inc. | 5.45 Million USD | -82.827% |
| Regen BioPharma, Inc. | 5.45 Million USD | -82.827% |
| NovAccess Global Inc. | 7.86 Million USD | -26.935% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 59.678% |
| Itoco Inc. | 1.65 Million USD | -503.575% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -386.36% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -64.953% |
| Kadimastem Ltd | 3.5 Million USD | -184.69% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2266.878% |
| CytoDyn Inc. | 127.89 Million USD | 92.198% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -23771.384% |
| Mobile Lads Corp. | 1.31 Million USD | -659.652% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -537.011% |
| Qrons Inc. | 1.48 Million USD | -570.243% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 9.663% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1133.689% |
| Rebus Holdings, Inc. | 5.24 Million USD | -90.347% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -63.523% |
| International Stem Cell Corporation | 5.27 Million USD | -89.085% |
| Bioxytran, Inc. | 3.24 Million USD | -207.063% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1494.416% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -116.109% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 75.661% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 55.185% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -392.647% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -82.147% |
| Neutra Corp. | 973.52 Thousand USD | -924.931% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 65.611% |
| PureTech Health plc | 125.58 Million USD | 92.055% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -165.575% |
| IXICO plc | 1.9 Million USD | -425.077% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 51.396% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 90.343% |
| CSL Limited | 18.62 Billion USD | 99.946% |
| Cellectis S.A. | 249.36 Million USD | 95.999% |